Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause ... More than a thousand of these were given a new inhaler to manage their condition, which contains three different ...

Opens in a new tab or window There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease ...

BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016 ... maintenance therapy dropped to 27,109 in 2020 but went back up in 2021 with 31,658 patients ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

is to work with Qualcomm to 'digitally upgrade' its Respimat inhaler, introducing a new connectivity solution to improve medication adherence in chronic obstructive pulmonary disorder (COPD ...

Inhalers may be prescribed to people who have a variety of health conditions both chronic and acute, including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. If you're new ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...